Table 2.

Prospective CMV analysis of tissue, serum and plasma from 18 patients with newly diagnosed high-grade glioma.

Patient	Histology		Demographics		Blood
	Diagnosis	WHO grade	Age at diagnosis	Gender	Real-time PCR* plasma (baseline), copy number/mL	Serum CMV IgG avidity index
1	GBM	IV	56	M	NEGATIVE	0.81
2	GBM	IV	76	M	NEGATIVE	N/A
3	GBM	IV	60	M	NEGATIVE	NEGATIVE
4	GBM	IV	70	F	NEGATIVE	NEGATIVE
5	GBM	IV	51	M	NEGATIVE	0.55
6	GBM	IV	48	F	NEGATIVE	NEGATIVE
7	GBM	IV	59	F	NEGATIVE	NEGATIVE
8	GBM	IV	46	F	NEGATIVE	0.76
9	GBM	IV	68	F	1.15E+02	0.82
10	GBM	IV	42	M	NEGATIVE	NEGATIVE
11	GS	IV	45	M	1.06E+02	0.73
12	GS	IV	89	F	2.49E+02	0.62
13	AA	III	30	M	NEGATIVE	N/A
14	AA	III	42	M	NEGATIVE	0.68
15	AA	III	32	F	NEGATIVE	NEGATIVE
16	AA	III	62	M	NEGATIVE	NEGATIVE
17	AA	III	64	F	NEGATIVE	0.73
18	AA	III	55	F	NEGATIVE	N/A
Positive controls	N/A	N/A	N/A	N/A	Towne CMV spiked into plasma at 1E3 and 1E5 copies/mL	N/A

Abbreviations: GBM, glioblastoma; GS, gliosarcoma; AA, anaplastic astrocytoma; N/A, not analyzed/not available.

^*Both the quantitative US17 real-time PCR assay and the COBAS AmliPrep/COBAS TaqMan IVD test were used for this analysis (results in the table are from testing with US17).